DK2094708T3 - En pyrrolopyrazin som syk-kinase-inhibitor - Google Patents

En pyrrolopyrazin som syk-kinase-inhibitor

Info

Publication number: DK2094708T3
Authority: DK; Denmark
Prior art keywords: synk; pyrrolopyrazine; kinase inhibitor; kinase; inhibitor
Prior art date: 2006-09-11

Application number

DK07842207.8T

Other languages

English (en)

Inventor

Timothy A Gillespy

Paul Eynott

Elizabeth M Allen

Kin T Yu

Asher Zilberstein

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2007-09-11

Publication date

2014-01-27

2007-09-11 Application filed by Sanofi Sa filed Critical Sanofi Sa

2014-01-27 Application granted granted Critical

2014-01-27 Publication of DK2094708T3 publication Critical patent/DK2094708T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK07842207.8T 2006-09-11 2007-09-11 En pyrrolopyrazin som syk-kinase-inhibitor DK2094708T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11
PCT/US2007/078103 WO2008033798A2 (en)	2006-09-11	2007-09-11	A pyrrolopyrazin as syk-kinase inhibitor

Publications (1)

Publication Number	Publication Date
DK2094708T3 true DK2094708T3 (da)	2014-01-27

Family

ID=39032357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07842207.8T DK2094708T3 (da)	2006-09-11	2007-09-11	En pyrrolopyrazin som syk-kinase-inhibitor

Country Status (32)

Country	Link
US (2)	US8658649B2 (da)
EP (1)	EP2094708B1 (da)
JP (1)	JP5161237B2 (da)
KR (1)	KR101443056B1 (da)
CN (2)	CN103804383A (da)
AR (1)	AR062745A1 (da)
AU (1)	AU2007296592B8 (da)
BR (1)	BRPI0716781A2 (da)
CA (1)	CA2663175C (da)
CL (1)	CL2007002617A1 (da)
CO (1)	CO6160236A2 (da)
CR (1)	CR10636A (da)
DK (1)	DK2094708T3 (da)
ES (1)	ES2437318T3 (da)
GT (1)	GT200900055A (da)
HN (1)	HN2009000455A (da)
IL (1)	IL197381A (da)
MA (1)	MA30781B1 (da)
MX (1)	MX2009002616A (da)
MY (1)	MY148107A (da)
NI (1)	NI200900021A (da)
NO (1)	NO20091265L (da)
NZ (1)	NZ575496A (da)
PE (1)	PE20081372A1 (da)
PT (1)	PT2094708E (da)
RU (1)	RU2440352C2 (da)
TN (2)	TN2009000049A1 (da)
TW (1)	TWI399379B (da)
UA (1)	UA94622C2 (da)
UY (1)	UY30584A1 (da)
WO (1)	WO2008033798A2 (da)
ZA (1)	ZA200901073B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2247592B1 (en)	2008-02-25	2011-08-31	F. Hoffmann-La Roche AG	Pyrrolopyrazine kinase inhibitors
CA2713718A1 (en)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
PT2250172E (pt)	2008-02-25	2011-11-30	Hoffmann La Roche	Inibidores de pirrolpirazina-cinase
CN101952295B (zh) *	2008-02-25	2013-11-20	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
CA2716223A1 (en)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
RU2010141560A (ru) *	2008-03-10	2012-04-20	Санофи-Авентис (Fr)	Лечение офтальмологических заболеваний
FR2929851B1 (fr) *	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es)	2008-12-03	2010-07-27	Sanofi Aventis	Tratamiento para la glomerulonefritis
EP2373655A1 (en)	2008-12-04	2011-10-12	Sanofi	Crystalline forms
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
PL2516434T3 (pl)	2009-12-23	2015-11-30	Takeda Pharmaceuticals Co	Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) *	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
MX2012013378A (es) *	2010-05-20	2013-01-24	Hoffmann La Roche	Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
RU2012152354A (ru)	2010-05-20	2014-06-27	Ф. Хоффманн-Ля Рош Аг	Производные пирролопиразина в качестве ингибиторов syk и jak
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2723739B1 (en)	2011-06-22	2016-08-24	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
WO2014029732A1 (en) *	2012-08-21	2014-02-27	F. Hoffmann-La Roche Ag	Pyrrolo[2,3-b]pyrazines as syk inhibitors
CN105555780B (zh) *	2013-07-31	2018-01-23	吉利德科学公司	Syk抑制剂
CA3129665A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020378630A1 (en)	2019-11-08	2022-05-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en)	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en)	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US6075037A (en)	1994-06-09	2000-06-13	Smithkline Beecham Corporation	Endothelin receptor antagonists
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2271767A1 (en)	1996-11-19	1998-05-28	Nathan B. Mantlo	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
JP2001516353A (ja)	1997-03-19	2001-09-25	ビーエーエスエフアクチェンゲゼルシャフト	ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用
AU7132998A (en)	1997-04-24	1998-11-13	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
EP1003744B1 (en)	1997-08-05	2005-06-01	Pfizer Products Inc.	4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
HUP0100348A3 (en)	1997-10-20	2002-12-28	Hoffmann La Roche	Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates
AU767599B2 (en)	1998-03-06	2003-11-20	Metabasis Therapeutics, Inc.	Novel prodrugs for phosphorus-containing compounds
CA2326185A1 (en)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
CA2326140A1 (en)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
WO1999061436A1 (fr)	1998-05-26	1999-12-02	Chugai Seiyaku Kabushiki Kaisha	Derives d'indole heterocycliques et derives de mono ou de di-azaindole
AU752474B2 (en)	1998-09-18	2002-09-19	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
SK287882B6 (sk) *	1999-12-24	2012-02-03	Aventis Pharma Limited	Azaindoles derivatives, pharmaceutical composition containing thereof and their use
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
US6770666B2 (en)	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de)	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
WO2001070743A1 (en)	2000-03-20	2001-09-27	Axys Pharmaceuticals, Inc.	Non-amidine containing protease inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2001082930A1 (en)	2000-05-03	2001-11-08	Tularik Inc.	Pyrazole antimicrobial agents
EP1294718A2 (en)	2000-06-14	2003-03-26	Warner-Lambert Company Llc	6,5-fused bicyclic heterocycles
AU2002211828A1 (en)	2000-10-02	2002-04-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (en)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP5039268B2 (ja)	2001-10-26	2012-10-03	アベンティス・ファーマスーティカルズ・インコーポレイテツド	ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja)	2003-08-06	2005-02-17	Japan Tobacco Inc.	縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
BRPI0513899A (pt) *	2004-07-27	2008-05-20	Sgx Pharmaceuticals Inc	moduladores de cinase heterocìclica de anel fundido
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
AU2005304952B2 (en)	2004-11-08	2013-04-04	Baxter Healthcare S.A.	Nanoparticulate compositions of tubulin inhibitors
AU2005309566A1 (en) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Bicyclic inhibitors or Rho kinase
US20110112101A1 (en)	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/en active Active
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/en active Search and Examination
- 2007-09-11 CA CA2663175A patent/CA2663175C/en not_active Expired - Fee Related
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP5161237B2 (ja)	2013-03-13
RU2009113615A (ru)	2010-10-20
JP2010502767A (ja)	2010-01-28
CN103804383A (zh)	2014-05-21
AU2007296592B2 (en)	2011-12-15
MX2009002616A (es)	2009-03-24
NO20091265L (no)	2009-04-03
CA2663175C (en)	2012-03-13
IL197381A0 (en)	2009-12-24
CA2663175A1 (en)	2008-03-20
EP2094708B1 (en)	2013-10-23
MA30781B1 (fr)	2009-10-01
CN101511838A (zh)	2009-08-19
WO2008033798A2 (en)	2008-03-20
WO2008033798A3 (en)	2008-05-15
TN2009000050A1 (en)	2010-08-19
KR20090063214A (ko)	2009-06-17
CL2007002617A1 (es)	2008-05-16
AR062745A1 (es)	2008-12-03
CR10636A (es)	2009-03-20
US8658649B2 (en)	2014-02-25
AU2007296592A1 (en)	2008-03-20
NI200900021A (es)	2010-01-29
TN2009000049A1 (en)	2010-08-19
KR101443056B1 (ko)	2014-09-22
UA94622C2 (en)	2011-05-25
CO6160236A2 (es)	2010-05-20
BRPI0716781A2 (pt)	2014-11-18
US20100035884A1 (en)	2010-02-11
ES2437318T3 (es)	2014-01-10
TWI399379B (zh)	2013-06-21
NZ575496A (en)	2011-09-30
HN2009000455A (es)	2012-02-13
MY148107A (en)	2013-02-28
ZA200901073B (en)	2009-12-30
EP2094708A2 (en)	2009-09-02
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
TW200829590A (en)	2008-07-16
UY30584A1 (es)	2008-05-02
GT200900055A (es)	2010-07-28
AU2007296592B8 (en)	2012-01-12
PE20081372A1 (es)	2008-11-27
US20140142110A1 (en)	2014-05-22
IL197381A (en)	2013-11-28

Publication	Publication Date	Title
DK2094708T3 (da)	2014-01-27	En pyrrolopyrazin som syk-kinase-inhibitor
CY2019001I1 (el)	2019-11-27	Υποκατεστημενες εναμινοκαρβονυλ ενωσεις
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2402317T3 (da)	2013-10-07	DGAT-inhibitor
DK2125748T3 (da)	2011-08-01	Acylaminopyrazol som FGFR inhibitorer
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK1937671T3 (da)	2010-04-26	Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2308841T3 (da)	2014-06-30	Phlorizinanaloge som SGLT2-inhibitorer
ATE524477T1 (de)	2011-09-15	Aziridinylepothilonverbindungen
DE602007011793D1 (de)	2011-02-17	Biaryl-ether-harnstoffverbindungen
DK2013519T3 (da)	2013-02-11	Tætningsarrangement
EP1985620A4 (en)	2012-08-15	COMPOUND 10a-AZALIDE
DK2383271T3 (da)	2013-10-07	Aminoquinoloner som GSK-3-inhibitorer
EP1998599A4 (en)	2010-12-08	LIGHT EMITTING DEVICE
ATE534010T1 (de)	2011-12-15	Zielfernrohr
DK2007396T3 (da)	2013-03-18	Enfumafungin-derivat som antimykotika
ITMI20060943A1 (it)	2007-11-13	Nessuno
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
DK1865940T3 (da)	2013-03-04	Alfaketoamidforbindelser som cysteinproteasehæmmere
SE0600338L (sv)	2007-08-16	Verktyg
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
EP2059496A4 (en)	2009-09-16	ACETYLENE COMPOUNDS